DECOY THERAPEUTICS · BIOTECH

Naming a new category of antiviral, and telling its story everywhere.

The challenge

Decoy Therapeutics engaged TMC Studio when its preclinical antiviral platform didn’t fit any existing category. The Nasdaq-listed company needed one story that investors, partners and press would remember.

Decoy Therapeutics website homepage with the line One Drug. Many Viruses. Many People.

The approach

Find what’s truly different. Pinned down what set the science apart: one drug designed to work across many viruses.

Name it. Led a two-day positioning workshop with the leadership team that turned it into a category: Designable Multi-Antivirals, or D-MAVs.

Codify it. Wrote the brand communications guidebook: positioning, three messaging pillars and voice.

Tell it everywhere. Carried the story into the 10-K, investor deck, business development materials, press releases and award submissions, and brought in the right partner to build a new website around it.

The results

A new category. D-MAVs became one clear message, used consistently from the 10-K to the investor deck.

The website. The positioning carried all the way through to the company website.

Recognition. Winner, 2026 BioTech Breakthrough Award for R&D Solution of the Year. Finalist, Fierce AI Innovation Awards.


“Deck looks terrific. It sets a very professional and polished tone.”

Rick Pierce, CEO, Decoy Therapeutics
Previous
Previous

Trade Estonia

Next
Next

Income Movement